Harrow Highlights Growing Clinical Evidence Supporting IHEEZO® and BYOOVIZ® at ASRS 2026 Annual Meeting

Harrow (HROW) presented three clinical studies at the ASRS 2026 Annual Meeting supporting its retina portfolio, specifically IHEEZO® (chloroprocaine HCl ophthalmic gel) and BYOOVIZ® (ranibizumab-nuna biosimilar). The presentation expands the clinical evidence base for these products in the ophthalmic disease management space, targeting physician adoption and patient outcomes in retinal care.

The accumulation of clinical and real-world evidence for both products addresses a critical need in ophthalmic therapeutics: building physician confidence in safety and efficacy profiles. For IHEEZO®, evidence supporting a low-viscosity ocular anesthetic gel can differentiate it in a competitive market. For BYOOVIZ®, biosimilar parity data remains essential as physicians transition from reference biologics like LUCENTIS®, particularly given cost-efficacy narratives in health systems.

This announcement reflects standard clinical-stage validation activity typical for specialty pharmaceutical companies. The timing—at a major retina specialist conference—targets key opinion leaders and prescriber networks. Success metrics depend on downstream adoption velocity and market penetration, not merely presentation acceptance.

Sector implication: Positive for the specialty ophthalmology segment within Health Care. Biosimilar competition in anti-VEGF therapies continues to expand, with clinical evidence serving as a primary differentiator. Harrow's evidence generation supports long-term market share stabilization in a mature but growing therapeutic area.